Packaging

US vs EU Digital Pharma: A Tale of Two Markets

12/03/25

The pharmaceutical sector is experiencing rapid evolution in how medicines and drug products reach patients, especially through digital channels. Two key models are emerging: digital pharmacies, which act as online resellers of pharmaceutical products, and direct-to-patient (D2P) platforms, where pharmaceutical companies control the complete supply chain from manufacture to delivery. While both models are being embraced in the U.S. and Europe, there are differences in how they operate in each region.

The U.S. Boom: fast Growth, big players, and unified regulations

In the U.S., the digital pharmacy market is experiencing rapid growth, projected to reach $240 billion by 2030, according to research firm The Insight Partners, at a compound annual growth rate (CAGR) of 17.25%. This is driven by an established e-commerce culture, high smartphone penetration, and rising healthcare costs pushing consumers toward cost-effective solutions. The entry of major players like Amazon has accelerated this transformation. Additionally, the market benefits from a unified regulatory approach under FDA oversight, although challenges in state-to-state enforcement remain.

Pharmacist using digital for pharma packaging

Europe: a fragmented market with diverse challenges

Europe presents a more complex landscape. While digital pharmacy adoption is growing at an 11.58% CAGR according to Statista data, progress varies significantly between countries due to differing healthcare systems, regulations, and digital maturity. Markets like Germany have quickly embraced online pharmacies. However, the regulatory diversity among EU member states creates challenges for pharmaceutical companies operating across multiple European markets.

Digital pharmacies face significant security challenges, especially regarding counterfeit medicines entering supply chains. The European Union Intellectual Property Office reports counterfeit medicines cost the EU pharmaceutical industry over €10 billion annually. These risks are particularly acute for online resellers, where patients and healthcare professionals cannot physically inspect products before purchase or distribution, and supply chain verification can be limited.

The role of packaging in securing the future of digital pharma

Both the U.S. and European markets are experiencing growth in digital pharmacies and D2P platforms, presenting significant challenges for pharmaceutical companies, especially regarding product security and traceability. Packaging plays a crucial role, both in terms of user experience design and in protecting against counterfeiting. Robust security measures and serialization systems are essential for digital pharmacies, while for D2P platforms, packaging should focus on user experience while meeting regional regulatory requirements. One thing is clear: for both cases, traceability remains crucial for patient safety.

The role of packaging in securing the future of digital pharma

Want to learn more about our packaging solutions?

Related News